In 2017, 1.8 million people were newly infected with HIV and nearly one million people died of AIDS. Johnson & Johnson (J&J) has revealed that it has completed enrolment procedures for its efficacy study of a HIV preventative vaccine from its subsidiary, Janssen. The phase IIb trial for the Imbokodo vaccine now has 2,600 female participants in the 18-35 age range from five African countries with high HIV rates. The treatment will include mosaic immunogens from a variety of viral gene subtypes behind the HIV virus, with the aim of triggering an immune response. In order to conduct this trial, Janssen and J&J have partnered up with the University of Pretoria (UP South Africa) as well as other partners including the World Health Organization (WHO) and the United Nations
Johnson & Johnson (J&J) has revealed that it has completed enrolment procedures for its efficacy study of a HIV preventative vaccine from its subsidiary, Janssen. The phase IIb trial for the Imbokodo vaccine now has 2,600 female participants in the 18-35 age range from five African countries with high HIV rates. The treatment will include mosaic immunogens from a variety of viral gene subtypes behind the HIV virus, with the aim of triggering an immune response. In order to conduct this trial, Janssen and J&J have partnered up with the University of Pretoria (UP South Africa) as well as other partners including the World Health Organization (WHO) and the United Nations